Every material Form 8-K abrdn Healthcare Investors has filed with the SEC since March 23, 2012, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Deloitte & Touche LLP resigned on September 6, 2023 as independent auditor of the Tekla Healthcare Investors fund, citing an anticipated independence issue tied to a pending transaction between Tekla Capital Management and abrdn Inc. The fund's Board approved KPMG LLP as the new auditor on September 7, 2023, for the fiscal year ending September 30, 2023. The filing reports no adverse opinions, disagreements or reportable events with Deloitte.
Deloitte & Touche resigned on September 6, 2023, due to an anticipated independence issue linked to a pending Tekla Capital Management and abrdn Inc. transaction.
The Audit Committee approved the resignation on September 7, 2023.
KPMG LLP was engaged on September 7, 2023 for the fiscal year ending September 30, 2023.
Deloitte's prior reports for fiscal 2022 and 2021 contained no adverse opinion, disclaimer or qualification, and the filing reports no disagreements or reportable events.
H&Q Healthcare Investors, a closed-end fund listed on the NYSE as HQH, said its Board of Trustees renewed its share repurchase program. The renewal lets the fund buy back up to 12% of its outstanding common shares in the open market for a one-year period ending July 10, 2014, replacing the current program that ends July 10, 2013. The Board said the goal is to reduce the discount between the share price and net asset value per share, though the filing gives no assurance of any specific repurchase amount or discount level.
Renewed program allows open-market purchases of up to 12% of outstanding common shares
Current program runs through July 10, 2013; renewal extends the period to July 10, 2014
Timing and amount of repurchases are at the discretion of Tekla Capital Management LLC, the fund's investment adviser
The filing states there is no assurance that repurchases will narrow the discount or raise the share price
The Board of Trustees authorized a renewal of the fund's share repurchase program, which allows open-market purchases of up to 12% of outstanding common shares for one year starting July 11, 2012. The board says the program aims to raise net asset value per share and narrow the gap between the share price and net asset value.
Renewed program allows open-market purchases of up to 12% of outstanding common shares
Current program runs through July 10, 2012; renewal covers the one-year period beginning July 11, 2012
Amount and timing of repurchases are at the discretion of investment adviser Hambrecht & Quist Capital Management LLC
Filing states there is no assurance of purchases at any specific discount level, amount or date
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every abrdn Healthcare Investors filing is on SEC EDGAR ↗. 8-K briefs of other companies →